This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Urit Medical Electronic Co., Ltd.. Active years: 2018.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2018
Title: Chengfeng Jiang: Innovator in Thalassemia Detection
Introduction
Chengfeng Jiang is a notable inventor based in Guilin, China. He has made significant contributions to the field of medical diagnostics, particularly in the detection of thalassemia. His innovative work has the potential to improve patient outcomes through rapid and accurate testing methods.
Latest Patents
Chengfeng Jiang holds 1 patent for his invention titled "Methods, compositions, and diagnostic kits for the detection of alpha and beta thalassemia." This patent discloses methods, compositions, and diagnostic kits designed for the rapid detection of specific types of α-thalassemia and β-thalassemia. The invention includes diagnostic kits, reagents, and methods that utilize real-time PCR to detect various thalassemia genotypes in multiple patient samples. Notably, the diagnostic kits can identify up to seven different α-thalassemia genotypes and twenty different β-thalassemia genotypes in a single multiplex real-time PCR reaction.
Career Highlights
Chengfeng Jiang is associated with Urit Medical Electronic Co., Ltd., where he continues to advance his research and development efforts. His work at this company underscores his commitment to enhancing medical diagnostic technologies.
Collaborations
Chengfeng has collaborated with notable colleagues, including Jinlan Xu and Jun Liu, to further his research initiatives. Their combined expertise contributes to the innovative solutions being developed in the field of medical diagnostics.
Conclusion
Chengfeng Jiang's contributions to thalassemia detection represent a significant advancement in medical diagnostics. His innovative methods and diagnostic kits have the potential to transform how thalassemia is diagnosed and managed, ultimately benefiting patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile